The window hypothesis: haemodynamic and nonhaemodynamic effects of b-blockers improve survival of patients with cirrhosis during a window in the disease

Krag, Aleksander; Wiest, Reiner; Albillos, Agustín; Gluud, Lise Lotte
July 2012
Gut;Jul2012, Vol. 61 Issue 7, p967
Academic Journal
The article presents information on the impact of the β blockers in terms of both haemodynamic and nonhaemodynamic on the patients suffering with cirrhosis in the liver. The advanced stage of cirrhosis causes variceal bleeding, spontaneous infections, ascites and develops the hepatorenal syndrome and hepatic encephalopathy. Information on the identification of surrogate makers of the blockers results of the blockers on the patients is also presented.


Related Articles

  • The Conservative and Interventional Treatment of the Complications of Liver Cirrhosis. Sauerbruch, Tilman; Appenrodt, Beate; Schmitz, Volker; Spengler, Ulrich // Deutsches Aerzteblatt International;2/21/2013, Vol. 110 Issue 8, p126 

    Background: It is estimated that 1 million persons in Germany suffer from hepatic cirrhosis, which is the final stage of chronic inflammation of the liver. Cirrhosis has multiple causes, all of which lead to structural changes of the liver and to portal hypertension. The main complications of...

  • Editorial: Beta-Blockers and the Prevention of Decompensation in Cirrhosis: Worth the Trouble. Northup, Patrick G; Henry, Zachary H // American Journal of Gastroenterology;Mar2012, Vol. 107 Issue 3, p428 

    Non-selective beta-blockers have been a cornerstone of therapy for prevention of esophageal variceal bleeding in cirrhosis patients for more than two decades. When lowering the hepatic vein portal pressure gradient (HVPG) below 12 mm Hg or decreasing the pressure by 20% from baseline, these...

  • Non-selective ß-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Leithead, Joanna A.; Rajoriya, Neil; Tehami, Nadeem; Hodson, James; Gunson, Bridget K.; Tripathi, Dhiraj; Ferguson, James W. // Gut;Jul2015, Vol. 64 Issue 7, p1111 

    Objective Recent data have suggested that nonselective ß-blockers (NSBB) are associated with increased mortality in patients with cirrhosis and refractory ascites. However, other evidence implies that NSBB may be beneficial in this setting by reducing bacterial translocation. Our aim was to...

  • Cirrhosis complications: Keeping them under control. Minor, Suzanne E.; Eliacin, Irmanie; Kashan, Sanaz; Whisenant, Ebony B. // Journal of Family Practice;Jun2015, Vol. 64 Issue 6, p338 

    The article focuses on the role of family physician in the identification and treatment of cirrhosis complications. Among the most common complications of cirrhosis are ascites, hepatic encephalopathy, and hepatorenal syndrome. It also discusses which patients with cirrhosis complications should...

  • Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension. Vespasiani-Gentilucci, Umberto; Rombouts, Krista // Gut;Apr2015, Vol. 64 Issue 4, p523 

    The article offers information on the boosting pigment epithelial-derived factor, which is a promising approach for the treatment of early portal hypertension (PHT). It mentions that it is responsible for many of the complications that occur in cirrhosis, including gastroesophageal varices,...

  • Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection. Citro, Vincenzo; Milan, Graziella; Tripodi, Francesca Saveria; Gennari, Antonio; Sorrentino, Paolo; Gallotta, Giovanni; Postiglione, Alfredo; Tarantino, Giovanni // Journal of Gastroenterology;Jan2007, Vol. 42 Issue 1, p79 

    In patients with cirrhosis, subclinical hepatic encephalopathy, which negatively affects the activity of daily living, is often unidentified. In a multicenter observational study, we investigated the possibility of detecting minimal neurological changes consistent with subclinical hepatic...

  • Drug therapies in liver disease. Collins, Peter; Ayres, Lachlan; Valliani, Talal // Clinical Medicine;Dec2013, Vol. 13 Issue 6, p585 

    The likelihood of a general physician encountering a patient with compensated and decompensated liver disease is increasing. This article provides an overview of pharmaceutical agents currently used in the management of cirrhosis and is designed to allow a better understanding of the rationale...

  • Identification, Prevention and Management of Risks Associated With Hepatic Encephalopathy -A Review. Yasmeen, Hina; Shah, Wafa Batool; Mehmood, Khawaja Tahir // Journal of Pharmaceutical Sciences & Research;2010, Vol. 2 Issue 12, p814 

    Hepatic encephalopathy (HE) is a neuropsychiatric complication of either acute or chronic hepatic insufficiency. Aim was to analyze the precipitating factors of hepatic encephalopathy and to determine therapeutic approach for treatment of HE. A retrospective study was carried out in Sir Ganga...

  • To block, or not to block in advanced cirrhosis and ascites: that is the question. Krag, Aleksander; Madsen, Bjørn Staehr // Gut;Jul2015, Vol. 64 Issue 7, p1015 

    The authors focus on a study conducted by researcher J.A. Leithead related to the usage of non-selective beta blockers (NSBB) in the treatment of cirrhosis and ascites. It mentions the higher rate of survival without a liver transplant in patients who received NSBB treatment. It states the...


Read the Article


Sign out of this library

Other Topics